论文部分内容阅读
目的 :探讨微包囊技术在解决胰岛移植免疫排斥问题中的作用。方法 :将用链脲霉素 (STZ)制备的合格糖尿病模型鼠 2 1只随机分为 3组 ,每组 7只。空囊组腹腔内植入 5 0 0～ 6 0 0个空囊 ,游离胰岛组植入经胶原酶消化制备的人胎胰岛细胞 10 0 0± 10 0个 ,微囊组植入 10 0 0± 10 0个微囊包裹的胰岛细胞。结果 :游离胰岛组和微囊组小鼠在完全停用胰岛素的情况下 ,术后血糖分别降至 7.94± 2 .36mmol.L-1和 7.0 7± 1.15mmol.L-1,与空囊组比较差异有统计学意义 (t=13.170 P <0 .0 0 1,t=2 4 .999 P <0 .0 0 1) ,分别持续 7.4 3± 3.4 2天和 78.4± 2 1.2 7天 (t =8.6 5P <0 .0 0 1)。结论 :该微囊化人胎胰岛移植具有良好的组织相容性和免疫隔离作用 ,明显延长移植胰岛的存活时间
Objective: To investigate the role of microencapsulation in solving the problem of islet rejection. Methods: Twenty-one eligible diabetic model rats (STZ) were randomly divided into three groups (n = 7). 500 ~ 600 empty pockets were implanted into the empty bag group, 100 0 ± 10 0 human fetal islet cells were prepared by collagenase digestion, and 100 0 ± 10 0 microencapsulated islet cells. Results: After insulin was completely withdrawn from the islets and microcapsules groups, the postoperative blood glucose decreased to 7.94 ± 2.36mmol.L-1 and 7.07 ± 1.15mmol.L-1, respectively, The difference was statistically significant (t = 13.170 P <0.001, t = 2.4999, P <0.001), respectively, lasting 7.4 3 ± 3.4 days and 78.4 ± 2 days = 8.6 5P <0 .0 0 1). Conclusion: The microencapsulated human fetal islet transplantation has a good histocompatibility and immune isolation, significantly prolong the survival time of transplanted islets